Selank

A heptapeptide studied for anxiety. Two small randomized trials in anxiety disorders report improvement, and the rest of the evidence is animal or laboratory work.

The basics

Human protocol on record	None published
Animal or laboratory figures	9
Published records retrieved	15
Registered trials	10
Certificate of analysis	Published by the partner
Regulatory status	Research-grade material, no approved human use

1. The protocol on record

Hard disclaimer. Figures below are transcribed from a published study or an approved label exactly as the source states them. They record what researchers administered in a trial population, not instructions for any person, and none of it is adjusted to you. Most compounds here have no approved human use. Do not act on any of it without a licensed prescriber who knows your history.

Amounts and schedules, human record

No published human protocol exists for Selank in the cited record. No amount, frequency or schedule can be given here without inventing it, and this page does not invent figures.

Animal and laboratory models (not human figures)

Phase or model	Amount	Frequency	Timing	Route	Duration	Source
Rat chronic foot-shock stress model	100 μg/kg	with each stress session	15 min before each stress session	intraperitoneal	not stated	source
Rat chronic foot-shock stress model	300 μg/kg	with each stress session	15 min before each stress session	intraperitoneal	not stated	source
Rat chronic foot-shock stress model	1000 μg/kg	with each stress session	15 min before each stress session	intraperitoneal	not stated	source
Rat restraint stress model	100 μg/kg	not stated	15 min prior to restraint stress	intraperitoneal	not stated	source
Rat restraint stress model	300 μg/kg	not stated	15 min prior to restraint stress	intraperitoneal	not stated	source
Rat restraint stress model	1000 μg/kg	not stated	15 min prior to restraint stress	intraperitoneal	not stated	source
Rat social stress model	100 mcg/kg	per day	not stated	intraperitoneal	20 days, under conditions of 20-day stress	source
Rat morphine withdrawal model	0.3 mg/kg	single dose	not stated	intraperitoneal	single dose	source
Rat ethanol withdrawal memory model	0.3 mg/kg	per day	not stated	intraperitoneal	7 days	source

Half-life and why the schedule looks like that

The cited record does not state a half-life, clearance value, or duration of action for selank itself, in humans or in animals. Not stated in the cited record. What the record does state, with the compound each statement actually belongs to: - Selank is described as a synthetic derivative of tuftsin that is "stable with respect to tissue peptidases" (PMID: 20919548, rat study). Stability to peptidases is not a half-life figure. - Patients with generalized anxiety showed a shortened half-life of endogenous leu-enkephalin in blood (tau(1/2) leu-enkephalin), a finding about enkephalin, not about selank (PMID: 18454096; also PMID: 11550013, which reports shortened enkephalin half-life during gen

Handling and storage

- Lyophilised storage: Not stated in the cited record. - Storage after reconstitution: Not stated in the cited record. - Temperature: Not stated in the cited record. - Light: Not stated in the cited record. - Stability duration: Not stated in the cited record. No approved label appears in the cited record, so no label storage instructions exist to transcribe.

These figures summarise what published research and approved labels describe. They are educational, not a recommendation or a personal protocol. Any dose, schedule, or decision to use a compound belongs with a licensed prescriber.

Open the interactive builder for reconstitution maths and a calendar →

2. Safety and harm reduction

Reported adverse effects

Effect	How often reported	Population	Source
Attention and memory impairment, asthenia, sedation, increase in sleep duration, sexual disturbances, emotional indifference, orthostatism	frequency not stated; these effects are attributed to phenazepam, and the trial reports that adding selank to phenazepam decreased their level during treatment and after tranquilizer withdrawal	randomized controlled trial, patients with anxiety-phobic, hypochondriac and somatoform disorders (70 patients; 30 on phenazepam alone, 40 on selank plus phenazepam)	PMID: 26356395
Anxiety indicators changed toward deterioration after a course of test substances; the changes after selank were less pronounced than with the comparison	frequency not stated	rat model, unpredictable chronic mild stress and non-stress conditions	PMID: 28280289

Cautions stated in the literature

Selank enhanced the anxiolytic effect of diazepam in rats under unpredictable chronic mild stress; the combination was the most effective condition in that model (PMID: 28280289).
Combined treatment with selank and phenazepam decreased the level of phenazepam's undesirable side-effects in patients with anxiety disorders (PMID: 26356395).
In a neuroblastoma cell culture, selank combined with GABA nearly completely suppressed the gene-expression changes produced by GABA alone, and selank combined with olanzapine altered the expression of more genes than olanzapine alone, suggesting selank may enhance the effect of olanzapine on the genes studied (PMID: 28293190).

Stop and get help

A severe or worsening reaction of any kind after administration.
Signs of an allergic reaction: hives, swelling of the face, lips, tongue or throat, difficulty breathing, or sudden widespread rash.
Signs of an injection-site infection: spreading redness, warmth, swelling, pain that increases rather than fades, pus, or fever.
Any effect that is unexpected and persistent, or that interferes with normal function.
Any circumstance in which the material's identity, purity, or condition is in doubt.

Pairings

Co-studied

Selank and Semax

Two neuroactive peptides measured in one brain-imaging study, in separate groups. Measured together is not the same as given together.

Open the pairing brief →

Selank at Peptara Labs

Read the third-party certificate of analysis before anything else. Research-grade material, research use only.

Open the Selank page